A Retrospective Registry Study Evaluating the Long-Term Efficacy and Safety of Superficial Radiation Therapy Following Excision of Keloid Scars

: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. : We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. : Medical records were reviewed of subjects treated for k...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical and aesthetic dermatology Vol. 13; no. 10; pp. 12 - 16
Main Authors Berman, Brian, Nestor, Mark S, Gold, Michael H, Goldberg, David J, Weiss, Eduardo T, Raymond, Isabelle
Format Journal Article
LanguageEnglish
Published United States Matrix Medical Communications 01.10.2020
Subjects
Online AccessGet full text
ISSN1941-2789
2689-9175

Cover

Loading…
Abstract : Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. : We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. : Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. : Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. : SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.
AbstractList : Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. : We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. : Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. : Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. : SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.
BACKGROUND : Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE : We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. METHODS : Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. RESULTS : Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. CONCLUSIONS : SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.
BACKGROUND: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE: We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. METHODS: Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. RESULTS: Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. CONCLUSIONS: SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.BACKGROUND: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE: We sought to assess keloid recurrence rates when superficial radiation therapy (SRT) was applied following surgical excision. METHODS: Medical records were reviewed of subjects treated for keloid scars followed by SRT (SRT-100™; Sensus Healthcare, Boca Raton, Florida) using a biologically effective dose (BED) of 30Gy and for whom the required retrospective data was available. Eligible subjects (N=61) were treated for 96 keloid scars with SRT. Subjects were male (48%) and female (52%) with a mean age of 38.87 years. Subjects were treated for ≥1 keloid scars following removal by sutured excision (93%) or tangential excision with secondary intention technique (7%). Almost all subjects (98%) received BED 30Gy with irradiation scheme of three 6Gy SRT treatments on Days 1, 2 and 3 following surgery. Mean energy of 100KV (73%) or 70KV (27%) were applied. RESULTS: Ten treated keloidectomy sites (10.4%) had recurrences (i.e., presence of any new tissue growth on the surgical scar) within 12 months increasing to 11 (12.7%) at 18 months. Kaplan-Meier survival probability cure rate was 85.6% from 24 months post-SRT treatment onwards. Transient hyperpigmentation was the most frequent adverse event and there were no malignancies in the treatment area during follow-up evaluations. CONCLUSIONS: SRT with a BED value of 30 Gy delivered to keloidectomy excision sites immediately following excision was well-tolerated and resulted in markedly fewer long-term recurrences than reported following keloidectomy alone. Most keloid scar recurrences occurred within one year. There were no malignancies during follow-up evaluations.
Author Berman, Brian
Goldberg, David J
Weiss, Eduardo T
Raymond, Isabelle
Nestor, Mark S
Gold, Michael H
Author_xml – sequence: 1
  givenname: Brian
  surname: Berman
  fullname: Berman, Brian
  organization: Dr. Raymond is with Memorial Health System in Boca Raton, Florida
– sequence: 2
  givenname: Mark S
  surname: Nestor
  fullname: Nestor, Mark S
  organization: Dr. Raymond is with Memorial Health System in Boca Raton, Florida
– sequence: 3
  givenname: Michael H
  surname: Gold
  fullname: Gold, Michael H
  organization: Dr. Raymond is with Memorial Health System in Boca Raton, Florida
– sequence: 4
  givenname: David J
  surname: Goldberg
  fullname: Goldberg, David J
  organization: Dr. Raymond is with Memorial Health System in Boca Raton, Florida
– sequence: 5
  givenname: Eduardo T
  surname: Weiss
  fullname: Weiss, Eduardo T
  organization: Dr. Raymond is with Memorial Health System in Boca Raton, Florida
– sequence: 6
  givenname: Isabelle
  surname: Raymond
  fullname: Raymond, Isabelle
  organization: Dr. Raymond is with Memorial Health System in Boca Raton, Florida
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33584951$$D View this record in MEDLINE/PubMed
BookMark eNpVkc9q3DAQh0VJaDZ_XiHo2IvBWsm2dAmEsGlCFgrZvZuxPN5V0UquJG_rp8grR6FJSecyDN_M9zvMOTlx3uEXsljWUhWKNdUJWTAlWLFspDojVzH-LHNxqapGfCVnnFdSqIotyMstfcYUfBxRJ3PEPO1MTGGmmzT1M10dwU6QjNvRtEe69m5XbDEc6GoYjAY9U3A93cCAaaZ-oJtpxJCJAUufoTf51Du63WOAcab33lr_-022-qNNfEP55gmtN1miIcRLcjqAjXj13i_I9n61vXso1j--P97drouRSZYK0UONEkXHFe94p6uqrpnWijFUSnaDFgyGoUSheslYL7peAIKAKsOac35Bbv5qx6k7YK_RpQC2HYM5QJhbD6b9nzizb3f-2DZSlKVssuDbuyD4XxPG1B5M1GgtOPRTbJdCqroslajy6vXnrH8hH0_gr_E2iuc
ContentType Journal Article
Copyright Copyright © 2020. Matrix Medical Communications. All rights reserved.
Copyright © 2020. Matrix Medical Communications. All rights reserved. 2020
Copyright_xml – notice: Copyright © 2020. Matrix Medical Communications. All rights reserved.
– notice: Copyright © 2020. Matrix Medical Communications. All rights reserved. 2020
DBID NPM
7X8
5PM
DatabaseName PubMed
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle PubMed
MEDLINE - Academic
DatabaseTitleList PubMed

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2689-9175
EndPage 16
ExternalDocumentID PMC7840087
33584951
Genre Journal Article
Review
GroupedDBID ---
53G
AAKDD
AAWTL
ABDBF
ACUHS
ADBBV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
DIK
E3Z
EBD
EBS
EJD
ESX
F5P
HYE
NPM
OK1
RPM
TUS
7X8
5PM
ID FETCH-LOGICAL-p181t-4da6e8e4b393b3bc55661cc911e998bfc41aff0e49d811d4bd4aea4a598b6333
ISSN 1941-2789
IngestDate Thu Aug 21 13:48:09 EDT 2025
Fri Jul 11 15:52:28 EDT 2025
Mon Jul 21 06:06:51 EDT 2025
IsPeerReviewed true
IsScholarly true
Issue 10
Keywords keloid scars
Keloids
recurrence rate
superficial radiation therapy
Language English
License Copyright © 2020. Matrix Medical Communications. All rights reserved.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-p181t-4da6e8e4b393b3bc55661cc911e998bfc41aff0e49d811d4bd4aea4a598b6333
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
ObjectType-Review-3
content type line 23
DISCLOSURES:Dr. Berman is a consultant and speaker for Sensus Healthcare. Dr. Nestor is a consultant, speaker, and member of the Advisory Board for Sensus Healthcare. Drs. Gold and Goldberg are speakers for Sensus Healthcare. Dr. Raymond is a full-time employee of and owns shares in Sensus Healthcare. Dr. Weiss has no relevant conflicts to disclose.
FUNDING:This study was sponsored by Sensus Healthcare, Boca Raton, Florida.
PMID 33584951
PQID 2489600945
PQPubID 23479
PageCount 5
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_7840087
proquest_miscellaneous_2489600945
pubmed_primary_33584951
PublicationCentury 2000
PublicationDate 2020-Oct
20201001
PublicationDateYYYYMMDD 2020-10-01
PublicationDate_xml – month: 10
  year: 2020
  text: 2020-Oct
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle The Journal of clinical and aesthetic dermatology
PublicationTitleAlternate J Clin Aesthet Dermatol
PublicationYear 2020
Publisher Matrix Medical Communications
Publisher_xml – name: Matrix Medical Communications
SSID ssj0000389574
Score 2.2452238
SecondaryResourceType review_article
Snippet : Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. : We sought to assess keloid recurrence...
BACKGROUND: Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE: We sought to assess...
BACKGROUND : Surgical treatment of keloid scars is associated with an approximately 70% recurrence rate at the excision site. OBJECTIVE : We sought to assess...
SourceID pubmedcentral
proquest
pubmed
SourceType Open Access Repository
Aggregation Database
Index Database
StartPage 12
SubjectTerms Retrospective Analysis
Title A Retrospective Registry Study Evaluating the Long-Term Efficacy and Safety of Superficial Radiation Therapy Following Excision of Keloid Scars
URI https://www.ncbi.nlm.nih.gov/pubmed/33584951
https://www.proquest.com/docview/2489600945
https://pubmed.ncbi.nlm.nih.gov/PMC7840087
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lj9MwELbYPSAuiDflJSNxq4KS2kmT44JaVtAtEpuVeotsx96HUFKVVDz-BH-ZGdt5oT0sXKLWSRzJ3yd7xp5vhpA3kRAKkEXZh-QBV1oGGc_AWQGsk9BwnRnc7zhZJ8dn_OMm3vQn-FZd0si36te1upL_QRXaAFdUyf4Dsl2n0AC_AV-4AsJwvRHGGMvW7OpWLQn_zm3xNhsd-HO68Jm8vSBqVVfnQQ4zMZZTBmyUS710Kox2YRmn-y3WrLab6F8wZ4HlRu7yDkyXwJj6O3a2-OHq8uA7n_TX-hI6UcIfC1319BsYu50A0-aGhZXoAsWT0xLXhWa0s_8Om1wN-d2AumtbAadVF_Ubth981Wsf_t9rLfBGG7tmA_f9AZjf4QB3to2VayfljEcBKnZHszYbsjMczME-LHuUWnv9uVierVZFvtjkB-SARWywsWMXbTDc4rmLQfBfu87n-Dt0dmCL5PfIXT-u9Mgx4j65pasH5PaJD5N4SH4f0RExaEsMaolBe2JQAIJ2xKAtMSjARB0xaG3ogBi0Iwb1xKAdMWhLDHzHEYNaYjwi-XKRvz8OfOWNYAsWXxPwUiQ61VyyjEkmVQxGf6QULIwa3HNpFI-EMaHmWZlGUcllyYUWXMRwM2GMPSaHVV3pp4QaHpZMzUIDZhBPy1mWKFQzZ_CsiFItJuR1O8gFTGx4WiUqXe-_FTOegncdZjyekCdu0Iuty8BSMAZ2M_gGEzIfwdE9gEnTx3eqywubPH2eckzD-OwG331O7vR0fEEOm91evwQTtJGvLHn-ANvyleI
linkProvider National Library of Medicine
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+Retrospective+Registry+Study+Evaluating+the+Long-Term+Efficacy+and+Safety+of+Superficial+Radiation+Therapy+Following+Excision+of+Keloid+Scars&rft.jtitle=The+Journal+of+clinical+and+aesthetic+dermatology&rft.au=Berman%2C+Brian&rft.au=Nestor%2C+Mark+S&rft.au=Gold%2C+Michael+H&rft.au=Goldberg%2C+David+J&rft.date=2020-10-01&rft.issn=1941-2789&rft.volume=13&rft.issue=10&rft.spage=12&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1941-2789&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1941-2789&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1941-2789&client=summon